Company Filing History:
Years Active: 2015-2025
Title: Innovator Spotlight: Douglas L Sheridan - Revolutionizing Therapeutic Antibodies
Introduction:
Douglas L Sheridan, a prolific inventor based in Branford, CT, has made significant contributions to the field of biotechnology with an impressive portfolio of 22 patents. His groundbreaking work focuses on developing cutting-edge antibodies for therapeutic purposes, particularly in the realms of cancer treatment and organ transplantation.
Latest Patents:
1. Humanized anti-CD200 antibodies and uses thereof: Sheridan's innovation includes antibodies that target CD200, showcasing potential applications in cancer therapy and organ transplant procedures. These proteins have the ability to revolutionize treatment strategies in these critical areas.
2. Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof: Another patent highlights Sheridan's engineered polypeptides designed to bind to human complement component C5 and serum albumin. This innovation opens doors to the development of multi-specific fusion proteins with diverse therapeutic possibilities.
Career Highlights:
Douglas L Sheridan is an integral part of Alexion Pharmaceuticals, Inc., a renowned biopharmaceutical company known for its groundbreaking research and development in rare diseases. Through his work at Alexion Pharmaceuticals, Sheridan has garnered recognition for his innovative approach to antibody-based therapies, solidifying his reputation as a formidable force in the biotech industry.
Collaborations:
Sheridan's impactful work is further enriched by collaborations with esteemed colleagues such as Paul P Tamburini and Bruce A Andrien, Jr. Together, they form a dynamic team driving innovation and pushing the boundaries of biotechnological advancements.
Conclusion:
In conclusion, Douglas L Sheridan's relentless pursuit of innovative antibody technologies underscores his commitment to advancing medical treatments and improving patient outcomes. His patents stand as a testament to his expertise and vision in the field of biotechnology, positioning him as a key figure in the ongoing quest for novel therapeutic solutions.